#### PROGENICS PHARMACEUTICALS INC

Form 4 April 18, 2007

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Boyd Thomas A

2. Issuer Name and Ticker or Trading

Symbol

**PROGENICS** 

PHARMACEUTICALS INC

[PGNX]

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year) 03/30/2007

5. Relationship of Reporting Person(s) to

Issuer

below)

(Check all applicable)

Director X\_ Officer (give title

10% Owner Other (specify

Sr. VP, Product Dev.

777 OLD SAW MILL RIVER ROAD

(Street)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

TARRYTOWN, NY 10591

(City)	(State)	(Zip) Tabl	le I - Non-I	Derivative	Secu	rities Acqu	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securi or(A) or Di (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/30/2007		D	5,000	D	\$ 0	28,676	D	
Common Stock	04/16/2007		M	1,500	A	\$ 17.19	30,426	D	
Common Stock	04/16/2007		S	1,500 (1)	D	\$ 26.814	28,926	D	
Common Stock	04/16/2007		M	500	A	\$ 13.625	29,426	D	
	04/16/2007		S	500 (1)	D	\$ 27.06	28,926	D	

### Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number proof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerci Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Securit
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Share
Non-Qualified Stock Option (right to buy)	\$ 13.625	04/16/2007		M	500	06/27/2005	06/28/2010	Common Stock	50
Non-Qualified Stock Option (right to buy)	\$ 17.19	04/16/2007		M	1,500	01/17/2005	01/18/2010	Common Stock	1,5

Relationshins

## **Reporting Owners**

Reporting Owner Name / Address	Kelationships						
	Director	10% Owner	Officer	Other			
Boyd Thomas A							
777 OLD SAW MILL RIVER ROAD			Sr. VP, Product Dev.				
TARRYTOWN NY 10591							

# **Signatures**

Thomas A. Boyd	04/18/2007		
**Signature of Reporting Person	Date		

Reporting Owners 2

#### Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 4

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale under a 10b5-1 Plan, which was established in accordance with the policies and procedures of the Issuer.
- The Reporting Person is exercising options under this grant in pre-established increments under and in accordance with provisions of a
- (2) previously established Plan of Sale under Rule 10b5-1, which was established in accordance with the policies and procedures of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.